2Pfaff WW, Blanton JW. Hepatitis antigenemia and survival after renal transplantation. Clin Transplant, 1997,11 (5 Pt 2): 4?6-4?9.
3Osborn MK, Lok AS. Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother, 2006, 57 (6): 1030-1034.
4Tassopoulos N, Hadziyannis S, Ciancian J, et al. Enteeavir is superior in treating patientswith chronic hepatitis B who have failed lamivudine therapy. Hepatology, 2004,40 Suppl:S673.
5Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine forthe treatment of lamivudine- refractory, HBeAg ( + )chronic hepatitis B.. Results of phase III study ETV-026. Hepatology, 2004,4(1 Suppl : S1152.
8Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerabitity of enteeavir in Lamivudine refractory chronic hepatitis B patients. Gastroenterology, 2005,129 (4) : 1198-1209.
9Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1927
8Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B.Expert Rev Anti Infect ther, 2004, 2:853-871.
9Dienstag JL. The value and limitation of long term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol, 2005, 42: 158-162.
10Chang TT, Hadziyannis S, Ciancian J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine therapy. Hepatology, 2002, 36:suppl. Abst 550.
